Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance

Area of Science:

• Molecular Biology
• Cancer Biology
• Cell Death Pathways

Background:

• The Akt pathway is frequently activated in human cancers, correlating with aggressive tumors and therapeutic resistance.
• Apoptosis, or programmed cell death, is a critical process often dysregulated in cancer.
• Bcl-2 family proteins, including Bax, regulate apoptosis.

Purpose of the Study:

• To investigate the mechanism by which Akt pathway activation confers resistance to chemotherapy.
• To determine the role of Akt-mediated phosphorylation of Bax in cancer cell survival.

Main Methods:

• Western blotting to detect phosphorylated Bax (p-Bax S184).
• Co-immunoprecipitation assays to assess protein interactions.
• Mitochondrial insertion assays for Bax.
• Analysis of The Cancer Genome Atlas (TCGA) database for Akt pathway and BAX expression correlation.

Main Results:

• Akt phosphorylates the pro-apoptotic protein Bax at serine 184 (S184).
• Akt-mediated Bax phosphorylation converts Bax into an anti-apoptotic protein by preventing its mitochondrial insertion and enabling binding to BH3 proteins.
• Bax phosphorylation correlates with cellular resistance to BH3 mimetics in ovarian cancer cells.
• TCGA data shows a strong correlation between upregulated Akt pathway and increased BAX levels in cancer patients.

Conclusions:

• Akt pathway activation promotes cancer cell survival and therapy resistance through Bax phosphorylation.
• Phosphorylated Bax acts as an anti-apoptotic protein, sequestering pro-apoptotic factors and preventing cell death.
• Targeting the Akt-Bax axis may represent a therapeutic strategy to overcome chemoresistance in cancers with upregulated Akt signaling.